Tag Archives | pharmacogenomics

Emerging Growth Stocks: Long Ideas in Life Science for 2019…Updates-Risk On…FED on Hold and “Patient”

Update ….Jan 30 2:45p  EST …FED to be Patient and Policy Stance is Appropriate FED to “wait and see” before raising rates-stocks soar. FED-“US Economy in a good place” NASDAQ up 2%, DOW up 1.73%, S&P up 1.53% XLV up 1.27%, IBB flat, XBI up 1.72%. Large cap biopharmas trail broad rally: AMGN,BIIB in the […]

Continue Reading 0

Large Cap Biopharmaceutical Performance 2018…Updates BMY CELG, XBI

1/7/19 After Close: Both BMY and CELG held today up over 3%. ==== Stay tuned Next Week for Updates from the J.P.Morgan Healthcare Conference 1/5/19 Friday’s broad-based biopharmaceutical rally boosts stocks out of a “Bear Market”which brought the XBI down 25% off highs to the  $64 level on December 24, 2018 and now at $75. […]

Continue Reading 0

Trading the Biotech Bottom in 2018 in an Ambivalent Market…Updates ASH TSRO XBI

Update-2 December 3 …Our Top Pick TSRO is up 58% on GSK Buyout We recommended Tesaro (TSRO) at $34 and it paid off today with a ~$5.1B buyout by GlaxoSmith Kline! Year End Rally Intact with XBI up over 3% to $84 handle, ====== Update-1 December 1… NASDAQ Rallies 0.79% on Nov 30 Our recent […]

Continue Reading 0

Biotech Bear Market: But It Is Time to Start Trading…11/9 Updates on Rally

Update at Close 11/9/18 Remain Cautious as Rally Fails The NASDAQ down 1.6% and Russell 2000 down 1.8%, sold off killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. The healthcare still looks good overall with the XLV down only 0.29% at $92.95. The XBI was crushed again down […]

Continue Reading 0

Biotech Momentum Lost Mired in Macro-Economic News Cycle: China, FED,Trade etc.

Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology  because […]

Continue Reading 0

Rayno BioBeat #6: Biotech Sell-Off with Broad Market Concerns…Updates

Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]

Continue Reading 0

Biotech Weakens Further: September Down 5% -Updates ABBV GWPH TSRO

Update 9/19 : Lightened up on Abbvie (ABBV) in low 90s with news of CA lawsuit on Humira kickbacks. Amgen (AMGN) hits 52 week high in $204 range, strong hold up 14.9% YTD. GW Pharmaceuticals (GWPH) rallies 6.61% to $159 for second day on cannabis trading frenzy; up 18.7% YTD with market cap $4.5B vs […]

Continue Reading 0

Biotech Weakness but why Large Caps?…Updates

Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but there was pronounced biotech weakness as well as in healthcare stocks one of the […]

Continue Reading 0

Biotech Snapshot: Healthcare Sector Remains Strong-Updates

8/24/18 After Close: Rally Continues with 10/11 Sectors Higher XLV finishes at all time high at $91.89 FED’s Powell Defends Gradual Interest Rate Policy despite Trump pressure Oil Surges 15 to $68.57 on supply concerns with Iran sanctions Major indices hit 52 week highs: S&P 500, Russell 2000, NASDAQ Composite IBB at $117.40 pushing toward 2018 FEB […]

Continue Reading 0

Biotech Snapshot During a Rally Day: No Summer Doldrums…Updates

Update-2… 8/12 Biotech and Healthcare Holds on Emerging Market Down Day IBB down 0.55%,  XBI down 0.43%, XLV down 0.43% EEM down 2.13%, QQQ down 0.76%. ==== Update-1 Rally Fades a Bit into the Close Biotech stocks were mixed trading closer to the flatline after the close on light summer volume. Macro issues such as drug […]

Continue Reading 0